Adalimumab use in patients with psoriasis and hepatitis B: a case series

No, Daniel J.; Amin, Mina; Wu, Jashin J.

doi:10.1111/jdv.14416

Cited by 3 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The data available for patients with PsO with concomitant HBV or HCV infection treated with systemic therapies are limited to case studies and small groups [43,47,48]. A systematic review found minimal risk of reactivation in low-risk patients seropositive for HBV or HCV treated with biologics, including secukinumab, and highlighted the considerable risk of reactivation in patients with chronic HBV [49].…”

Section: Hbv and Hcvmentioning

confidence: 99%

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence

Merola

Feldman

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Psoriasis (PsO) is a common, systemic, chronic, inflammatory disease characterized by key clinical symptoms, including itching, pain, and scaling. PsO is associated with a high prevalence of comorbidities, including other autoimmune diseases and malignancies. Furthermore, special populations, such as pregnant, pediatric, and elderly patients, and those with erythrodermic PsO, are challenging to treat and require tightly monitored disease and treatment management. Because certain populations have demographic or clinical characteristics that can affect the presentation of PsO and complicate treatment responses, these patient populations are largely excluded from clinical trials; therefore, most clinical evidence for the treatment of these patients is derived from case reports and series. Secukinumab, a fully human monoclonal interleukin-17A antibody, has been shown in several clinical trials to be effective and safe for the treatment of PsO; however, these studies offer only limited data on the use of secukinumab in patients with chronic illnesses or in special populations. This review explores the use of secukinumab for PsO in special populations, including pregnant women, children, elderly people, patients with erythrodermic PsO, and those with chronic illnesses, including latent tuberculosis, hepatitis B and C, HIV, multiple sclerosis, and malignancies.

show abstract

Section: Hbv and Hcvmentioning

confidence: 99%

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence

Merola

Feldman

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…Histoplasmosis can become life-threatening (20% mortality) when it presents as an opportunistic infection in patients receiving anti-TNF therapy [ 10 ]. Adalimumab is a monoclonal antibody that inhibits TNF, a cytokine involved in the pathogenesis of many inflammatory disease states including the activation of macrophages [ 11 ]. Consequently, the patient’s phagocytic macrophages were unable to eliminate the yeast or create a barrier of granulomas to prevent spreading via the lymphatic system [ 3 ].…”

Section: Discussionmentioning

confidence: 99%

Cave diving for a diagnosis: Disseminated histoplasmosis in the immunocompromised

Mirza

Rodriguez

2018

IDCases

View full text Add to dashboard Cite

show abstract

Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies

et al. 2020

View full text Add to dashboard Cite

SUMMARY The past 2 decades have seen a revolution in our approach to therapeutic immunosuppression. We have moved from relying on broadly active traditional medications, such as prednisolone or methotrexate, toward more specific agents that often target a single receptor, cytokine, or cell type, using monoclonal antibodies, fusion proteins, or targeted small molecules. This change has transformed the treatment of many conditions, including rheumatoid arthritis, cancers, asthma, and inflammatory bowel disease, but along with the benefits have come risks. Contrary to the hope that these more specific agents would have minimal and predictable infectious sequelae, infectious complications have emerged as a major stumbling block for many of these agents. Furthermore, the growing number and complexity of available biologic agents makes it difficult for clinicians to maintain current knowledge, and most review articles focus on a particular target disease or class of agent. In this article, we review the current state of knowledge about infectious complications of biologic and small molecule immunomodulatory agents, aiming to create a single resource relevant to a broad range of clinicians and researchers. For each of 19 classes of agent, we discuss the mechanism of action, the risk and types of infectious complications, and recommendations for prevention of infection.

show abstract

Adalimumab use in patients with psoriasis and hepatitis B: a case series

Cited by 3 publications

References 10 publications

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence

Cave diving for a diagnosis: Disseminated histoplasmosis in the immunocompromised

Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies

Contact Info

Product

Resources

About